Introduction
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) [1] [2] [3] . An estimated 120-200 million individuals worldwide and about 1% of the general population in Switzerland are chronically infected with HCV. About 50% of the chronic HCV infections in Switzerland are due to genotype 1 [4] . While the incidence of acute hepatitis C has declined significantly since the introduction of anti-HCV screening of blood and blood products in 1990, the number of patients presenting with decompensated cirrhosis and HCC is expected to increase further, attaining a peak around 2020 [1, 5] . More than 50% of the individuals at risk may currently be unaware of their infection. Strategies to increase testing and detection rates are currently being explored (e.g., screening of populations at risk vs. birth cohort screening) [6, 7] . Fifty to 80% of acutely infected individuals develop persistent infection. Of these, 2-20% will develop liver cirrhosis within the first 20 years, and accumulating evidence suggests that disease progression may increase in a nonlinear fashion thereafter [8] . Once cirrhosis is established, the rate of HCC development is 1-6% per year. Factors associated with more frequent and rapid progression to cirrhosis are, among others, higher age at the time of infection, male sex, alcohol consumption, coinfections with the human immunodeficiency virus (HIV) or hepatitis B virus (HBV), nonalcoholic fatty liver disease and smoking. Comprehensive management of chronic hepatitis C (CHC) takes these factors into consideration and aims at improving the ones that can be modified (alcohol abstinence; weight loss, regular physical activity and other measures to control the metabolic syndrome; vaccination against HBV [and hepatitis A virus]; smoking cessation including cannabis) [9] . While non-invasive methods for fibrosis assessment are actively being pursued [10] , liver biopsy remains the reference for grading and staging of CHC. The Metavir and Ishak scoring systems are most often applied. Fibrosis stages are classified from 0 (absence of fibrosis) to 4 (cirrhosis) in the Metavir system [11] , and from 0 to 6 in the Ishak system [12] . The decision to treat CHC is based on the analysis of numerous variables and should take into account the specific situation of each patient. Treatment is clearly recommended for patients with Metavir fibrosis stage ≥2 who do not have any contraindications. For other patients, decisions will have to be made on an individual basis. Additional factors that come into consideration are, among others, the (biological) age and general condition of the patient, the patient's personal and professional plans, the duration of HCV infection, the risk of developing cirrhosis, the likelihood of response to therapy, and comorbidity. For the last 10 years, standard therapy of CHC consisted of pegylated interferon-α (PEG-IFN-α) combined with ribavirin (RBV) for (16-)24-48(-72) weeks, yielding sustained virological response (SVR) rates of 40-50% in patients infected with HCV genotype 1 and~80% in patients infected with genotypes 2 and 3. Definitions of virological response patterns are provided in table 1. Polymorphisms near the IL28B gene have recently been identified as strong predictors of the outcome of IFN-α-based antiviral therapy (reviewed in [13, 14] ). A number of laboratories offer IL28B genetic testing, but its role in clinical practice and decision making, if any, remains to be defined. A first generation of directly acting antivirals, the NS3-4A protease inhibitors telaprevir (TPV; Incivo ® ) and boceprevir (BOC; Victrelis ® ), has recently been approved for the treatment of CHC genotype 1. TPV and BOC have to be combined with PEG-IFN-α and RBV in order to avoid the rapid selection of HCV strains resistant to antiviral therapy [15, 16] . Triple therapy comprising TPV or BOC increases SVR rates to~70% in treatment-naïve patients with CHC genotype 1 [17] [18] [19] . In treatment-experienced patients, SVR rates depend on the virological response to previous therapy with PEG-IFN-α and RBV, ranging from >80% in patients with previous relapse to~50% in patients with previous partial response and~30% in patients with previous null response [20] [21] [22] . Treatment schedules comprising TPV or BOC have more side effects than PEG-IFN-α and RBV, and should be managed carefully. A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex, as discussed below [23] . These expected developments represent a significant challenge and will stretch current resources. The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC. It is based on the results of recently published phase III clinical trials performed in treatment-naïve and treatment-experienced patients (ADVANCE [17] , ILLUMINATE [19] and REALIZE [20] for TPV as well as SPRINT-2 [18] , RESPOND-2 [21] and PROVIDE [22] for BOC), and take into account the recently updated American Association for the Study of Liver Diseases (AASLD) Practice Guidelines [3] as well as the labels approved by the US Food and Drug Administration, the European Medicinal Agency, and Swissmedic. Current European Association for the Study of the Liver (EASL) Clinical Practice Guidelines [2] are expected to be updated shortly. In addition, different national guidelines are in preparation. Therefore, as recommendations are emerging and as real-life data and practical experience on the use of TPV and BOC are still limited, it is strongly recommended to initiate and pursue triple therapy comprising TPV or BOC only in close collaboration with an expert centre.
Practical use of telaprevir and boceprevir
TPV is available in the form of 375-mg film-coated tablets and has to be taken at a dose of 750 mg every 8 hours (i.e., two tablets every 8 hours), with a meal or a snack containing~20 g of fat to increase bioavailability. BOC is available in the form of 200-mg capsules and has to be taken at a dose of 800 mg every 8 hours (i.e., 4 capsules every 8 hours), with a meal or a snack. Dosing every 8 ± 1 hour rather than 3 times per day is important to maintain inhibitory drug serum concentrations and to avoid antiviral resistance development. TPV and BOC should never be used alone, and doses should never be reduced. When used alone, these drugs will not be effective and will cause emergence of HCV strains with resistance to antiviral therapy that could be difficult to treat subsequently. RBV can be taken with the first dose of TPV or BOC in the morning and with the last dose of TPV or BOC in the evening. TPV and BOC are only approved for use in patients with HCV genotype 1 infection. The development of antiviral resistance is more frequent in subtype 1a than 1b but this should not influence therapeutic decision making. 1 The term "undetectable" in this paper refers to HCV RNA below the limited of detection (as opposed to the limit of quantitation) of a sensitive real-time PCR assay. 2 Relates to triple therapy comprising telaprevir. 3 Relates to triple therapy comprising boceprevir, including a 4-week lead-in phase of pegylated interferon-α and ribavirin. 4 Designated as early virological response in the recent EASL Clinical Practice Guidelines (ref.
2). 5 Formerly designated as slow virological response. table 1 for definitions of virological response patterns); P, pegylated interferon-α; R, ribavirin; T, telaprevir; wks, weeks.
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Data on the safety and efficacy of TPV and BOC in patients with HIV coinfection are emerging. TPV and BOC should be used only in close collaboration with an expert in these patients.
There is no data in liver transplant recipients, hemodialysis patients and children, and the use of TPV and BOC in these situations is currently proscribed. In registration trials, TPV was used with PEG-IFN-α2a 180 µg per week plus RBV 1000-1200 mg per day and BOC was used with PEG-IFN-α2b 1.5 µg/kg per week plus RBV 600-1400 mg per day. However, both forms of PEG-IFN-α may be used with RBV and either TPV or BOC. PEG-IFN-α is contraindicated in decompensated cirrhosis. Strict contraception must be followed during and for 6 months after the end of triple therapy because of the potential teratogenicity of RBV.
Who should be treated with triple therapy comprising TPV or BOC?
Triple therapy will represent a new standard for most treatment-naïve patients with CHC genotype 1 as well as treatment-experienced patients with a relapse or partial response to previous therapy with PEG-IFN-α and RBV (table 2) . Treatment of CHC is expected to change significantly within the next few years, with the arrival of better tolerated and 
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Swiss Med Wkly. 2012;142:w13516 even more efficacious new drugs as well as the advent of IFN-free/sparing regimens [27] [28] [29] [30] . These developments shall significantly improve the outlook for our patients. Therefore, deferring treatment may be considered in patients who's treatment can be safely postponed. Treatment-naïve patients with favourable baseline predictors (HCV RNA <4 x 10 5 IU/ml, absence of advanced fibrosis or cirrhosis) who achieve a rapid virological response (RVR; see table 1) have excellent chances to achieve SVR with 24 weeks of therapy with PEG-IFN-α and RBV alone [31] . Therefore, a 4-week lead-in with PEG-IFN-α and RBV may be considered in patients with the above-mentioned favourable baseline predictors and treatment continued without adding TPV or BOC for a total of 24 weeks in those who achieve RVR. Lead-in with PEG-IFN-α and RBV may also be considered if there are doubts concerning the tolerance or adherence to PEG-IFN-α and RBV backbone therapy. There is currently only limited data on the use of BOC in patients with previous null response. In general, retreatment of previous null responders has to be considered carefully, as SVR rates remain limited, especially in patients with cirrhosis. Inclusion of such patients into clinical trials involving quadruple therapy or IFN-sparing regimens may be considered. Lead-in with PEG-IFN-α and RBV may be considered in previous null responders, especially in cirrhotics, with the addition of TPV or BOC only in case of ≥1 log decline of HCV RNA at week 4. Subanalysis of the REALIZE trial revealed that 54% of the patients with ≥1 log decline after 4 weeks of lead-in with PEG-IFN-α and RBV achieved SVR with triple therapy comprising TPV, compared to only 15% of those with a decline of HCV RNA <1 log [32] . Careful monitoring and stopping rules, as detailed below, shall reduce the risk of selecting HCV strains resistant to antiviral therapy. While long-term consequences of the selection of such strains are presently unknown, antiviral resistance is likely to affect future treatment options [15, 16] . CHC, chronic hepatitis C; PEG-IFN-α, pegylated interferon-α; RBV, ribavirin. • Consider the natural history of hepatitis C and factors affecting disease progression.
Specific treatment algorithms
• Considerate treatment indication crucial (Treat the disease, not the infection!).
• Triple therapy comprising TPV or BOC increases SVR rates to ~70%, with shortened treatment duration in ~½.
• Advances will come at the expense of new adverse effects and increased cost.
• Antiviral therapy will become more complex (patient education, adherence, treatment milestones, adverse effect management, laboratory infrastructure and turnaround time, antiviral resistance).
• Limited or no data in patients with high unmet need (especially those with HIV coinfection and recurrent hepatitis C after liver transplantation).
• Available resources will be stretched.
• Liaise with an expert center. table 1 for definitions of virological response patterns); P, pegylated interferon-α; R, ribavirin; T, telaprevir; wks, weeks.
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Figure 2
Boceprevir-based triple therapy. (A) Treatment-naïve patients with CHC of genotype 1 without cirrhosis. (B) Treatment-experienced patients with CHC genotype 1 and previous relapse or partial response without cirrhosis. (C) All cirrhotic patients and prior null responders. B, boceprevir; BPR = B + P + R; P, pegylated interferon-α; R, ribavirin; RVR8, rapid virological response at week 8 (see table 1 for definitions of virological response patterns); wks, weeks.
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